No Data
Express News | Clearside Biomedical Appoints DR. Glenn Yiu to Its Scientific Advisory Board
Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery
- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide Insights and Real-World Experience with Suprachoroidal Drug Delivery - - Target Profile for CLS-AX in Wet AMD Landscape
Why Is Clearside Biomedical Stock Gaining Today?
Oppenheimer initiated coverage on Clearside Biomedical Inc (NASDAQ:CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal (SCS) space.Oppe
Wedbush Maintains Clearside Biomedical(CLSD.US) With Buy Rating, Raises Target Price to $5
Wedbush analyst Andreas Argyrides maintains $Clearside Biomedical(CLSD.US)$ with a buy rating, and adjusts the target price from $4 to $5.According to TipRanks data, the analyst has a success rate of
Express News | Clearside Biomedical Inc : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $5
Express News | Clearside Biomedical Shares Are Trading Higher After Oppenheimer Initiated Coverage With an Outperform Rating and a Price Target of $5